High Doses of Colchicine Act As "Silver Bullets" Against Severe COVID-19

被引:7
|
作者
Lilov, Alexander [1 ]
Palaveev, Kiril [1 ]
Mitev, Vanyo [2 ]
机构
[1] Sofia Dist Hosp, Specialized Hosp Act Treatment Pneumopneumonia Pht, Pulmonol, Sofia, Bulgaria
[2] Med Univ Sofia, Chem & Biochem, Sofia, Bulgaria
关键词
obesity; survival; colchicine; nlrp3; inflammasome; covid-19;
D O I
10.7759/cureus.54441
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
A 48-year-old patient with a weight of 120 kg with type 2 diabetes mellitus, hypertension, and gout was hospitalized on the third day of the COVID-19 diagnosis. His general condition is relatively good, oxygen saturation is 89%. Despite starting standard treatment, on the seventh day from the onset of symptoms, the patient deteriorated sharply (oxygen saturation dropped to 74%). The negative development of the disease is interrupted with a loading dose of colchicine of 6 mg. This is a typical case of the life-saving effect of high but safe doses of colchicine in high-risk COVID-19 patients.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Effects of Different Corticosteroid Doses in Elderly Unvaccinated Patients with Severe to Critical COVID-19
    Scialo, Filippo
    Mariniello, Domenica Francesca
    Nigro, Ersilia
    Komici, Klara
    Allocca, Valentino
    Bianco, Andrea
    Perrotta, Fabio
    D'Agnano, Vito
    LIFE-BASEL, 2022, 12 (11):
  • [42] The Centrality of Obesity in the Course of Severe COVID-19
    Liu, Danfei
    Zhang, Tongyue
    Wang, Yijun
    Xia, Limin
    FRONTIERS IN ENDOCRINOLOGY, 2021, 12
  • [43] Effects of Different Anticoagulation Doses on Moderate-to-Severe COVID-19 Pneumonia With Hypoxemia
    Nadeem, Amin Ur Rehman
    Naqvi, Syed M.
    Chandy, Kurian G.
    Nagineni, Venkata V.
    Nadeem, Rashid
    Desai, Shreya
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (08)
  • [44] Eosinophilia in Asthma Patients Is Protective Against Severe COVID-19 Illness
    Ferastraoaru, Denisa
    Hudes, Golda
    Jerschow, Elina
    Jariwala, Sunit
    Karagic, Merhunisa
    de Vos, Gabriele
    Rosenstreich, David
    Ramesh, Manish
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE, 2021, 9 (03) : 1152 - +
  • [45] Hypertension and severe COVID-19
    Kow, Chia Siang
    Ramachandram, Dinesh Sangarran
    Hasan, Syed Shahzad
    HYPERTENSION RESEARCH, 2023, 46 (05) : 1353 - 1354
  • [46] High vaccine effectiveness against severe COVID-19 in the elderly in Finland before and after the emergence of Omicron
    Baum, Ulrike
    Poukka, Eero
    Leino, Tuija
    Kilpi, Terhi
    Nohynek, Hanna
    Palmu, Arto A.
    BMC INFECTIOUS DISEASES, 2022, 22 (01)
  • [47] Colchicine in Recently Hospitalized Patients with COVID-19: A Randomized Controlled Trial (COL-COVID)
    Pascual-Figal, Domingo A.
    Roura-Piloto, Aychel E.
    Moral-Escudero, Encarnacion
    Bernal, Enrique
    Albendin-Iglesias, Helena
    Teresa Perez-Martinez, M.
    Antonio Noguera-Velasco, Jose
    Cebreiros-Lopez, Iria
    Hernandez-Vicente, Alvaro
    Vazquez-Andres, David
    Sanchez-Perez, Carmen
    Khan, Amjad
    Sanchez-Cabo, Fatima
    Garcia-Vazquez, Elisa
    INTERNATIONAL JOURNAL OF GENERAL MEDICINE, 2021, 14 : 5517 - 5526
  • [48] Clinical outcome of patients with COVID-19 Pneumonia treated with corticosteroids and colchicine in Colombia
    Miguel Alejandro Pinzón
    Doris Cardona Arango
    Juan Felipe Betancur
    Santiago Ortiz
    Héctor Holguín
    Carolina Arias Arias
    Bernardo J. Muñoz Palacio
    Michael Amarillo
    Juan Felipe Llano
    Pablo Montoya
    Annals of Clinical Microbiology and Antimicrobials, 20
  • [49] Colchicine for COVID-19: targeting NLRP3 inflammasome to blunt hyperinflammation
    Aldo Bonaventura
    Alessandra Vecchié
    Lorenzo Dagna
    Flavio Tangianu
    Antonio Abbate
    Francesco Dentali
    Inflammation Research, 2022, 71 : 293 - 307
  • [50] Colchicine - From rheumatology to the new kid on the block: Coronary syndromes and COVID-19
    Surma, Stanislaw
    Basiak, Marcin
    Romanczyk, Monika
    Filipiak, Krzysztof J.
    Okopien, Boguslaw
    CARDIOLOGY JOURNAL, 2023, 30 (02) : 297 - 311